| DB ID | MyCo_3510 |
| Title | Fungal biomarker monitoring and CT scans for early detection of invasive fungal disease in neutropenic hematological patients |
| Year | 2021 |
| PMID | 34710391 |
| Fungal Diseases involved | Invasive fungal infection |
| Associated Medical Condition | None |
| Genus | None |
| Species | None |
| Organism | None |
| Ethical Statement | The CEDMIC trial was approved by the institutional review board or independent ethics committee at each institution and conducted in accordance with the principles of the Declaration of Helsinki (UMIN000010411). |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Japan |
| Cohort | In the CEDMIC trial, 413 hematological patients aged be- tween 19 and 78 years, who had planned to undergo intensive chemotherapy or HCT, were included in an intent-to-treat (ITT) analysis. Serum GM and βDG were tested at least once in 342 (82.8%) and 378 (91.5%) patients, respectively. |
| Cohort No. | 378 |
| Age Group | 19-78 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | 0.0037 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Analytic |
| Analysis Method | Fungitec G Test |
| ELISA kits | Fungitec G Test Kit (MK II “Nissui”, Seika-gaku Kogyo, Tokyo, Japan) , Wako β- glucan assay Kit (Fujifilm Wako Chemicals, Osaka, Japan). |
| Assay Data | None |
| Validation Techniques used | Fungitec G Test |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
